Quote:
Originally Posted by Susanne C.
I can't help but feel that most of the impetus for Lyrica came from the expiration of the patent for Neurontin.
|
Yes, I seem to recall a discussion here along those lines -- timing strategies of pharmaceutical companies holding new or improved versions of older meds in the pipeline in reserve for when current patents lapse -- though I cannot find the thread in the archives. (It's late, I'm tired, and not hitting on best search terms of late...
)
Lyrica & Neurontin wouldn't be the only ones.
Doc